Hypericum extract LI 160: Clinical Trials

8 trials of Hypericum extract LI 160, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 terminated, 1 unknown, 1 withdrawn. 8 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Completed 5, Terminated 1, Unknown 1, Withdrawn 1
Phase 21Completed 1

Follow Hypericum extract LI 160: new trials by email Literature Review of Hypericum extract LI 160 trials Research Report on Hypericum extract LI 160

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis
St. John's Wort, Photodynamic diagnostic and therapy - Peritoneal Carcinomatosis
Phase 3UnknownUniversity Hospital Tuebingen502017-07-312017-10-27
St. John's Wort in the Treatment of Raynaud's Phenomenon
St. John's Wort, Lactose - Raynaud's Disease
Phase 3CompletedLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's202007-03-012009-07-14
Sertraline Compared With Hypericum Perforatum (St.John's Wort) in Treating Depression
Zoloft 50 mg, St. John's Wort 600 mg - Depression, Unspecified Adult Solid Tumor, Protocol Specific
Phase 3CompletedWake Forest University Health Sciences22004-03-012021-09-09
Homeopathy Assessment in Terms of the Consumption of Analgesics After Knee Ligamentoplasty
Arnica montana, 5 CH, Bryonia alba, 5 CH, Hypericum perforatum, 5 CH - Pain
Phase 3TerminatedUniversity Hospital, Grenoble1652003-12-012006-11-14
St. John's Wort Extract LI 160 for the Treatment of Atypical Depression
St. John's Wort extract, Placebo - Atypical Depression
Phase 3CompletedCassella-med GmbH & Co. KG2012002-12-012009-03-16
St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD)
Hypericum perforatum (St. John's wort) - Anxiety Disorders, Mental Health
Phase 2 / Phase 3CompletedNational Center for Complementary and Integrative Health (NCCIH)562002-08-012007-09-26
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
St. John's wort - Chronic Myeloproliferative Disorders, Fatigue
Phase 3CompletedMemorial Sloan Kettering Cancer Center1999-12-012013-01-18
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Hypericum perforatum, docetaxel, placebo - Adult Solid Tumor, Breast Cancer
Phase 3WithdrawnAlliance for Clinical Trials in Oncology2016-07-12

Conditions studied

Anxiety Disorders (1)  ·  Blast Crisis (1)  ·  Breast Neoplasms (1)  ·  Burkitt Lymphoma (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Depression (1)  ·  Esthesioneuroblastoma, Olfactory (1)  ·  Fatigue (1)  ·  Generalized Anxiety Disorder (1)  ·  Head and Neck Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Immunoblastic Lymphadenopathy (1)  ·  Immunoglobulin Light-chain Amyloidosis (1)  ·  Intraocular Lymphoma (1)  ·  Leukemia (1)

Sponsors

Alliance for Clinical Trials in Oncology (1)  ·  Cassella-med GmbH & Co. KG (1)  ·  London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  National Center for Complementary and Integrative Health (NCCIH) (1)  ·  University Hospital Tuebingen (1)  ·  University Hospital, Grenoble (1)  ·  Wake Forest University Health Sciences (1)

Countries

United States (3)  ·  Canada (1)  ·  France (1)  ·  Germany (1)

Top investigators

Antonius A. Miller, MD (1)  ·  David J. Straus, MD (1)  ·  Edward G. Shaw, MD (1)  ·  Janet E Pope, MD, MPH (1)  ·  Lionel D. Lewis, MD (1)  ·  Stefan Beckert, Prof. Dr. (1)  ·  Wei Zhang, MD (1)

Results publications

PMID 10853874, PMID 36999619

NIH funding

U10CA081851 (1)